Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer


    EDMONTON, Jan. 28 /CNW/ - Quest PharmaTech Inc. ("Quest" or the
"Company") today announced that it has signed a collaborative research
agreement with the BC Cancer Agency (the "BCCA") to develop a combination
therapy for the treatment of lung cancer. The potential treatment will utilize
the Company's lead oncology product, SL052, with various immunotherapeutic
agents. Research has shown that photodynamic therapy (PDT) can augment the
therapeutic effects of immunomodulators such as antibodies, antigens,
cytokines and immunoadjuvants in cancer patients.
    Under the terms of the agreement, the BCCA, with Dr. Mladen Korbelik as
the principle investigator, will investigate therapeutic and mechanistic
aspects of anti-tumor effects achieved by combining photodynamic therapy (PDT)
based on Quest's photosensitizer, SL052, with various immunotherapeutic
agents.
    PDT uses light to activate anti-cancer drugs, but has also been shown to
stimulate the body's immune system to fight the disease. Dr. Korbelik, a
Senior Scientist at the BCCA and a Clinical Professor at the University of
British Columbia, is a pioneer and leader in this area of research. For the
past 20 years, he has been involved in PDT studies aimed at improving
treatment of solid tumors. His research has provided direct evidence of the
induction of tumor immunity by PDT; and demonstrated that PDT can be
effectively potentiated by adjuvant immunotherapy.
    "Using targeted treatments with better delivery and manipulating the
body's own immune system to fight the disease means patients would experience
fewer side effects," said Dr. Korbelik. Quest has a strong intellectual
property position to use SL052 with immunotherapy. The combination therapy
technology has already received patents from United Kingdom, France, Germany,
Switzerland and Australia, and patents are pending in the USA and Canada.

    Background:

    About the BC Cancer Agency: The BCCA, an agency of the Provincial Health
Services Authority, is renowned world wide for leading edge research and its
population-based approach to cancer care. The mission of the BCCA is to reduce
the incidence of cancer; to reduce the mortality rate of people with cancer;
and to improve the quality of life of people living with cancer. With more
than 2000 employees, the BCCA provides a comprehensive cancer control program
for the people of British Columbia which links prevention, early detection,
diagnosis and treatment, supportive care, rehabilitation, palliative care,
education, research, and support for community programs. In recognition that
its provincial mandate to effect cancer control for the province cannot be
realized via current methods of cancer treatment that are aimed at treatment
of late stage disease, the BCCA has placed emphasis upon translational
research to spearhead new modalities in cancer control, particularly those
aimed at early detection and more effective therapeutic interventions.

    About Quest PharmaTech Inc: Quest PharmaTech Inc. is a publicly traded
(TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to
build shareholder value through discovery, development and commercialization
of new pharmaceutical products. It is developing a series of products for the
treatment of cancer and dermatological conditions based on its unique
photodynamic and sonodynamic therapy platform. The Company's lead dermatology
product, SL017, is a topical formulation that is currently undergoing a 90
patient clinical trial in Canada for hair removal applications. The Company's
lead oncology product, SL052, is scheduled to enter a Phase I clinical trial
during the second half of 2008. Quest recently signed an agreement with a
multinational technology development company to receive $3,000,000 to develop
oncology products based on its SonoLight technology.

    "TSX Venture Exchange has neither approved nor disapproved of the
    information contained herein."

    Web site: www.questpharmatech.com

    %SEDAR: 00008400E



For further information: Dr. Madi R. Madiyalakan, CEO, Tel.: (780)
448-1400 (Ext. 204), madi@questpharmatech.com